"Anew Labs presented its first AI-designed therapy at the American Association of Immunologists' annual meeting, showcasing a small molecule designed to inhibit IL-17, a cytokine involved in autoimmune diseases."
"The molecule targets a protein-protein interaction, a category of drug target that has been deemed undruggable due to the large and flat binding surfaces that conventional small molecules cannot disrupt."
"Anew Labs claims its AI has found a way to effectively target this interaction, marking a significant advancement in drug discovery technology."
"The unit operates from Shanghai, Singapore, and San Jose, California, and is led by a team of 36 core members, with plans for future presentations at major scientific conventions."
Anew Labs, ByteDance's drug discovery unit, presented its first AI-designed therapy at an immunology conference in Boston. The therapy targets IL-17, a cytokine linked to autoimmune diseases. Anew Labs also introduced AnewOmni, a generative framework trained on 5 million biomolecular complexes, claiming to design functional molecules across all scales. ByteDance joins the AI drug discovery field, competing with Isomorphic Labs, Anthropic, and Insilico Medicine. The unit operates from multiple locations and has a team of 36 members, with plans for future presentations at major conventions.
Read at TNW | Artificial-Intelligence
Unable to calculate read time
Collection
[
|
...
]